Gene: KRAS ×
Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913240
rs121913240
KRAS
0.020 GeneticVariation BEFREE Mutations in RAS genes (HRAS G13R, KRAS G12D, KRAS Q61R, NRAS Q61R) were detected in benign lesions and HRAS Q61R, NRAS Q61K mutations in PTCs. 31085772

2019
dbSNP: rs121913529
rs121913529
KRAS
0.020 GeneticVariation BEFREE KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer. 31085763

2019
dbSNP: rs121913240
rs121913240
KRAS
0.020 GeneticVariation BEFREE The BRAF T1799A mutation was detected in 10 PTC cases, while two different NRAS mutations in codon 61 (C181A and A182G) were found in 2 PTC cases. 30361901

2018
dbSNP: rs121913529
rs121913529
KRAS
0.020 GeneticVariation BEFREE Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. 27127178

2016
dbSNP: rs1137282
rs1137282
KRAS
0.010 GeneticVariation BEFREE We found rs11246050 in NLRP6 (dominant model, OR/95% CI: 2.028/1.091-3.769, p = 0.025), rs2286742 and rs3740530 in HABP2 (recessive model, OR/95% CI: 9.644/1.307-71.16, p = 0.026 and 3.989/1.413-11.26, p = 0.009), rs2736098 in TERT (recessive model, OR/95% CI: 2.322/1.028-5.242. p = 0.042) and rs62054619 in GAS8-AS1 (recessive model, OR/95% CI: 2.219/1.067-4.617, p = 0.033) were associated with the risk of PTC. rs1137282 in KRAS (dominant model, OR/95% CI: 0.5430/0.3192-0.9236, p = 0.024), rs1347591 and rs4461062 in NUP93 (dominant model, OR/95% CI: 0.6121/0.4128-0.9076, p = 0.015 and 0.6156/0.4157-0.9117, p = 0.015) were associated with low risk of distant metastatic disease in PTC patients. rs33954691 in TERT was associated with the risk of RR-PTC under dominant model (OR/95% CI: 3.161/1.596-6.262). 30826992

2019
dbSNP: rs121913238
rs121913238
KRAS
0.010 GeneticVariation BEFREE Mutations in RAS genes (HRAS G13R, KRAS G12D, KRAS Q61R, NRAS Q61R) were detected in benign lesions and HRAS Q61R, NRAS Q61K mutations in PTCs. 31085772

2019
dbSNP: rs712
rs712
KRAS
0.010 GeneticVariation BEFREE These results supported the role of the KRAS rs712 polymorphism as a potential genetic biomarker for the extension of PTC. 25201577

2014